Who are Placebo followed by Fisetin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-followed-by-fisetin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Placebo followed by Fisetin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo followed by Fisetin (Placebo followed by Fisetin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Senolytic agent. Area: Gerontology / Aging-related conditions.

marketed Senolytic agent Multiple targets including PI3K/Akt and p38 MAPK pathways in senescent cells Gerontology / Aging-related conditions Small molecule Live · refreshed every 30 min

Target snapshot

Placebo followed by Fisetin (Placebo followed by Fisetin) — Wake Forest University Health Sciences. Fisetin is a natural flavonoid that acts as a senolytic agent, selectively eliminating senescent cells that accumulate with aging.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo followed by Fisetin TARGET	Placebo followed by Fisetin	Wake Forest University Health Sciences	marketed	Senolytic agent	Multiple targets including PI3K/Akt and p38 MAPK pathways in senescent cells

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Senolytic agent class)

Wake Forest University Health Sciences · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo followed by Fisetin — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-followed-by-fisetin. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab